Drug intelligence / Profile preview

sotigalimab + carboplatin + paclitaxel

Development stage: Phase 2
Lead developer: Pyxis Oncology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This is an investigational triplet drug combination consisting of sotigalimab, carboplatin, and paclitaxel. **Sotigalimab** is a monoclonal antibody targeting CD40, functioning as an agonist to activate antigen-presenting cells and enhance antitumor immune response. **Carboplatin** is a platinum-based chemotherapeutic agent that induces DNA crosslinking, leading to apoptosis in rapidly dividing cancer cells. **Paclitaxel** is a taxane-based chemotherapeutic agent that stabilizes microtubules and inhibits cell division. The combination aims to provide synergistic antitumor activity by combining immune activation with cytotoxic chemotherapy.

Targets

CD40 (Cluster of differentiation 40 receptor)DNAMicrotubuleTUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on sotigalimab + carboplatin + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sotigalimab + carboplatin + paclitaxel.